These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 7620925

  • 1. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
    Ries M, Zenker M, Klinge J, Keuper H, Harms D.
    J Pediatr Hematol Oncol; 1995 Aug; 17(3):260-4. PubMed ID: 7620925
    [Abstract] [Full Text] [Related]

  • 2. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults.
    Ries M, Klinge J, Rauch R, Trusen B, Zenker M, Keuper H, Harms D.
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):346-51. PubMed ID: 8888740
    [Abstract] [Full Text] [Related]

  • 3. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B, Ries M, Zenker M, Rauh M, Beinder E, Keuper H, Harms D.
    Semin Thromb Hemost; 1998 Nov; 24(6):599-604. PubMed ID: 10066156
    [Abstract] [Full Text] [Related]

  • 4. In vitro simulation of therapeutic thrombolysis with microtiter plate clot-lysis assay.
    Stief TW.
    Clin Appl Thromb Hemost; 2006 Jan; 12(1):21-32. PubMed ID: 16444431
    [Abstract] [Full Text] [Related]

  • 5. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
    Samama M, Nguyen G, Desnoyers P, Lourenco DM, Fretault J, Horellou MH, Conard J, Szwarcer E, Verdy E, Vahanian A.
    Fundam Clin Pharmacol; 1988 Jan; 2(6):509-23. PubMed ID: 3149257
    [Abstract] [Full Text] [Related]

  • 6. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
    Dewerchin M, Lijnen HR, Stassen JM, De Cock F, Quertermous T, Ginsberg MH, Plow EF, Collen D.
    Blood; 1991 Aug 15; 78(4):1005-18. PubMed ID: 1831057
    [Abstract] [Full Text] [Related]

  • 7. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M, Lijnen HR, Keber D, Collen D.
    Thromb Haemost; 1989 Dec 29; 62(4):1083-7. PubMed ID: 2515603
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V, Pannell R.
    Thromb Res; 1986 Oct 15; 44(2):217-28. PubMed ID: 3097872
    [Abstract] [Full Text] [Related]

  • 10. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L, Sandesara J, Yang G, Vagher JP, Caprini JA.
    Thromb Haemost; 1986 Aug 20; 56(1):71-9. PubMed ID: 2946093
    [Abstract] [Full Text] [Related]

  • 11. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards.
    Brommer EJ.
    Thromb Res; 1984 Apr 15; 34(2):109-15. PubMed ID: 6539513
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 13. The role of alpha 2-antiplasmin in the inhibition of clot lysis in newborns and adults.
    Ries M, Klinge J, Rauch R, Keuper H, Harms D.
    Biol Neonate; 1996 Jun 30; 69(5):298-306. PubMed ID: 8790908
    [Abstract] [Full Text] [Related]

  • 14. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 15. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
    Martin U, Sponer G, Strein K.
    Blood Coagul Fibrinolysis; 1993 Apr 03; 4(2):235-42. PubMed ID: 8388740
    [Abstract] [Full Text] [Related]

  • 16. Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase).
    Musselman DR, Tate DA, Oberhardt BJ, Abruzzini AF, Blauwet MB, Koch G, Dehmer GJ.
    Am J Cardiol; 1994 Mar 15; 73(8):544-9. PubMed ID: 8147298
    [Abstract] [Full Text] [Related]

  • 17. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR, Gardell SJ.
    Thromb Haemost; 1992 Aug 03; 68(2):165-9. PubMed ID: 1412162
    [Abstract] [Full Text] [Related]

  • 18. Activation of the fibrinolytic system.
    Robison AK, Collen D.
    Cardiol Clin; 1987 Feb 03; 5(1):13-9. PubMed ID: 3103919
    [Abstract] [Full Text] [Related]

  • 19. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V, Pannell R.
    Thromb Haemost; 1987 Jun 03; 57(3):372-3. PubMed ID: 3116707
    [No Abstract] [Full Text] [Related]

  • 20. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT, Francis CW, Marder VJ.
    J Lab Clin Med; 1992 Jul 03; 120(1):120-8. PubMed ID: 1613318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.